Inhibrx Biosciences Inc.
INBX
Market Cap$213.66M
Close$
$9.62
34.6% downside
Current Fair Value
34.6% downsideOvervalued by 34.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $213.66 Million |
|---|---|
| Enterprise Value | $19.17 Million |
| Dividend Yield | $0.85 (5.75880758807588%) |
| Earnings per Share | $-5.12 |
| Beta | 2.88 |
| Outstanding Shares | 14,475,904 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.13 |
|---|---|
| PEG | -0.85 |
| Price to Sales | - |
| Price to Book Ratio | 1.23 |
| Enterprise Value to Revenue | 11.05 |
| Enterprise Value to EBIT | -0.05 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Inhibrx Inc
88 employeesInhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...